Capillary Hemangioblastoma - 11 Studies Found
Terminated |
: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease :
: 2009-11-16 : Drug: Avastin Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months |
Completed |
: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 :
|
Active, not recruiting |
: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease :
: 2000-06-06 |
Enrolling by invitation |
: Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) : Von Hippel-Lindau Disease : 2014-04-05 : Drug: Vorinostat |
Terminated |
: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow :
|
Completed |
: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma :
: 2007-12-26 : Drug: Sunitinib The study drug will be administered on an outpatient basis. The starting dose will be 50 |
Completed |
: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease :
|